Other AKT inhibitors, such as MK-2206 (NCT00848718 and NCT01480154), ipatasertib (NCT03673787), and afuresertib (NCT01476137), have also been studied in clinical trials targeting advanced melanoma. The gene discussed is AKT1; the disease is melanoma.